| abstract |
The present invention relates to a compound of formula (I) wherein R1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, or lower alkoxy substituted by halogen; R2 ishydrogen or lower alkyl; R3, R4 form together with the N-atom to which they are attached a non aromatic heterocyclic group, selected from R5 is hydrogen or halogen; R6 is phenyl, unsubstituted or substituted by cyano, halogen, lower alkyl, lower alkoxy, CF3, -(CH2)2O-lower alkyl, C(O)-lower alkyl or C(O)O-lower alkyl, or is pyridinyl, unsubstituted or substituted by CF3, or is -C(O)-phenyl; R7 ishydrogen or lower alkoxy; R8 is phenyl, lower alkyl or -C(O)O-lower alkyl; R9 is hydrogen or S(O)2-lower alkyl; R10 is hydrogen or cycloalkyl; X is -CH2- or -C(O)-; p is 1 or 2; n is 1, 2 or 3; o is1 or 2; or to a pharmaceutically suitable acid addition salt thereof which are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |